Assembly Biosciences Inc (ASMB) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Assembly Biosciences Inc. (ASMB) is running a Phase 1a/1b trial called “A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes.” The goal is to see if its new oral drug ABI-1179 looks safe and well tolerated, and to measure how the body absorbs and clears it, which is the key first step before any larger efficacy studies.
The study tests ABI-1179, an oral tablet, against a matching placebo in people with recurrent genital herpes caused by HSV-2. The drug is meant to become a new treatment option if later trials show it can reduce outbreaks and is safe over longer use.
Participants are randomly assigned to either ABI-1179 or placebo so results are fair and balanced. The study is triple-blinded, meaning patients, study doctors, and site staff do not know who gets the active drug, and it uses a parallel design with different groups taking either single or multiple doses mainly to assess treatment safety.
The trial began after initial submission on November 8, 2024, and is now listed as completed, signaling that dosing and follow-up are finished. The most recent update on March 20, 2026, shows that the sponsor has refreshed key information, even though full results have not yet been posted, which matters for timing any next clinical step or partnership talks.
The update suggests ASMB is moving its HSV-2 program along, which can support sentiment that management is executing on its pipeline beyond hepatitis B and other core areas. For investors, clean safety data here could open the door to Phase 2 and improve the company’s narrative versus antiviral peers, while any issues might weigh on the stock and shift focus back to better-established players in the herpes market.
The study has been completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about ASMB’s potential, visit the Assembly Biosciences Inc drug pipeline page.